Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Boston Scientific Corporation (BSX) Price & Performance

Goldman Sachs Physical Gold ETFTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Goldman Sachs Physical Gold ETF vs Boston Scientific Corporation — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.55, while Boston Scientific Corporation trades at $50.33 (market cap $74.19B). The key difference: Goldman Sachs Physical Gold ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

AAAUBSX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$108.14
52-Week Low
$32.74$42.63
Market Cap
$74.19B
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

No Aura AI signal available yet.

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX